Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The authors concluded that most male pseudohermaphrodites should be raised as females, recommending early gender assignment and appropriate alterations to better support coping and development.

Finasteride reduces inflammation and improves immune response after trauma by altering hormone levels.

This research suggests that the enzyme Phospholipase D from E. coli is a strong candidate as the underlying cause of benign prostatic hyperplasia, potentially mediated by its conversion to lysophosphatidic acid in the prostate.

Dutasteride reduces DHT more effectively than finasteride.

This abstract introduces androgenic alopecia as the most common form of non-cicatricial alopecia, which predominantly affects men but also has a significant occurrence in women; however, specific research results or conclusions about treatments or mechanisms are not reported in the summary.

This review discusses various aspects of hirsutism in women, including causes, hormonal influences, and treatment approaches, but reports no new findings.

This study found that altered testosterone metabolism and changes in cytochrome P450 mono-oxygenase expression are significantly associated with cardiac hypertrophy in human hearts and spontaneously hypertensive rats.

This study found that intracrine androgen signaling via 5α-reductase is essential for optimal endometrial decidualization and vascular development during this process in mice.

In testosterone-induced AGA mouse models, this study found that a dual-drug-loaded cationic nanoemulsion of minoxidil and finasteride enhanced follicle-associated retention, supporting hair regeneration while reducing systemic absorption and showing good skin compatibility, indicating a promising approach for androgenetic alopecia treatment.

This study found that Ishophloroglucin A from brown seaweed may treat androgenic alopecia by inhibiting 5α-reductase and promoting hair growth-related factors in human dermal papilla cells.

In this study, researchers reviewed non-pharmacological treatments for androgenetic alopecia, finding that substances like caffeine, rosemary oil, and saw palmetto may stimulate hair growth or inhibit dihydrotestosterone. They emphasize the need for multicenter clinical trials to further assess these natural products' efficacy in clinical practice.

This study reports that taxifolin from enzymatic hydrolysis effectively regulates dermal papilla cell apoptosis and promotes hair growth by increasing IGF-1 and reducing TGF-β1, though it shows less inhibition of DHT compared to minoxidil.

This case report describes a 28-year-old woman with facial, abdominal, and thigh hirsutism who showed little improvement after 5 months of Metformin and spironolactone treatment.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

This study found that platycodon ethanol extract showed potential as a natural ingredient for hair loss prevention by increasing radical scavenging ability, inhibiting inflammation, and affecting DHT generation in laboratory experiments.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

This review discusses the pathways of androgen biosynthesis and reports no new findings, highlighting the need to understand the interplay between the classic and backdoor pathways.

This study suggests that in human osteoblast-like cells, the 5alpha-reductase type 1 isozyme predominantly catalyzes the conversion of testosterone to DHT, which may play a role in bone homeostasis.

This review discusses idiopathic hirsutism, potential underlying mechanisms, and various therapeutic approaches without providing new clinical results, and emphasizes the need for further research on well-defined patient groups.

This article discusses the enzyme pathways involved in androgenetic alopecia and the role of finasteride in reducing dihydrotestosterone levels to promote hair growth; it reports no new clinical results.

This article discusses the role of androgens in hair follicle changes, explaining how dihydrotestosterone contributes to hair thinning on the scalp, while promoting thicker facial hair in men, and reports no new clinical results.

This article reviews studies showing AT-Grow as effective in treating benign prostatic disease due to its anti-androgen properties but reports no new findings on its effect on hair growth.

This article reviews the molecular mechanisms involved in androgenetic alopecia and the androgen's paradoxical role in hair growth, but reports no new experimental findings.

This review discusses the molecular mechanisms of masculinization involving androgen signaling and their roles in male embryonic development and conditions like hypospadias and prostate cancer, and reports no clinical results.

This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.

This article discusses the hormonal mechanisms contributing to acne and suggests dietary changes to reduce these hormones but reports no new clinical results.

In this review, the role of DHT in male-type obesity and metabolic diseases is discussed, with increased levels potentially exacerbating cardiovascular disease risk; the paper reports no new results.

This study found that finasteride decreased DHT-stimulated AR activity and cell growth in prostate cancer cells with mutant AR, but not in those with wild type AR.